Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure

INTRODUCTION: We report a comprehensive summary of the safety outcomes in adult patients with moderate-to-severe psoriasis with up to 5 years of exposure to ixekizumab. METHODS: Long-term safety of the IL-17A antagonist ixekizumab was assessed from 17 randomized trials. Treatment-emergent adverse ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Christopher E. M., Gooderham, Melinda, Colombel, Jean-Frederic, Terui, Tadashi, Accioly, Ana P., Gallo, Gaia, Zhu, Danting, Blauvelt, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209552/
https://www.ncbi.nlm.nih.gov/pubmed/35624407
http://dx.doi.org/10.1007/s13555-022-00743-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209552/
https://www.ncbi.nlm.nih.gov/pubmed/35624407
http://dx.doi.org/10.1007/s13555-022-00743-9

Ejemplares similares